

# LINCOLN PHARMACEUTICALS LIMITED

"LINCOLN HOUSE", B/H. SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380 060.

UN-AUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED ON 30.06.2013

(Rs. in Lacs)

PART - I									
PARTICULARS	CONSOLIDATED				STANDALONE				
	QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED		
	30.06.2013	31.03.2013	30.06.2012	31.03.2013	30.06.2013	31.03.2013	30.06.2012	31.03.2013	
	(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	
1	Income from operations								
	(a) Net Sales/income from operation (Net of excise duty)	3795.38	5755.44	2954.49	19287.87	3742.60	5861.64	2954.27	19092.05
	(b) Other operating income	205.29	197.01	70.69	668.65	180.62	75.38	68.10	469.62
	<b>Total income from operations (net)</b>	<b>4000.67</b>	<b>5952.45</b>	<b>3025.18</b>	<b>19956.52</b>	<b>3923.22</b>	<b>5937.02</b>	<b>3022.37</b>	<b>19561.67</b>
2	Expenses								
	(a) Cost of materials consumed	911.70	957.65	727.28	3911.13	599.69	653.94	728.29	3416.75
	(b) Purchases of stock-in-trade	1395.66	2686.55	938.77	8715.11	1813.81	3321.38	938.77	9211.46
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	-96.26	335.37	-95.16	81.04	-65.21	328.78	-95.16	117.69
	(d) Employee benefits expense	488.06	429.61	431.12	1770.90	418.26	374.44	400.92	1597.23
	(e) Depreciation and amortisation expense	85.76	79.42	51.54	264.84	55.02	52.30	50.23	207.94
	(f) Other expenses	797.57	781.00	746.95	3291.06	725.48	685.38	745.07	3162.10
	<b>Total expenses</b>	<b>3582.49</b>	<b>5269.60</b>	<b>2800.50</b>	<b>18034.08</b>	<b>3547.05</b>	<b>5416.22</b>	<b>2768.12</b>	<b>17713.17</b>
3	<b>Profit/(Loss) from operations before other income,finance costs and exceptional items (1-2)</b>								
		418.18	682.85	224.68	1922.44	376.17	520.80	254.25	1848.50
4	Other income								
		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items(3+ 4)</b>								
		418.18	682.85	224.68	1922.44	376.17	520.80	254.25	1848.50
6	Finance costs								
		145.23	230.73	104.06	784.04	93.12	190.10	104.17	715.91
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items(5 - 6)</b>								
		272.95	452.12	120.62	1138.40	283.05	330.70	150.08	1132.59
8	Exceptional items								
		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	<b>Profit / (Loss) from ordinary activities before tax (7 + 8)</b>								
		272.95	452.12	120.62	1138.40	283.05	330.70	150.08	1132.59
10	Tax expense								
		-35.09	-10.36	39.88	184.97	-66.99	13.12	37.80	151.32
11	<b>Net Profit / (Loss) from ordinary activities after tax (9 - 10)</b>								
		308.04	462.48	80.74	953.43	350.04	317.58	112.28	981.27
12	Extraordinary items (net of tax expense )								
		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	<b>Net Profit / (Loss) for the period (11 - 12)</b>								
		308.04	462.48	80.74	953.43	350.04	317.58	112.28	981.27
14	Share of profit / (loss) of associates*								
		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority interest *								
		-16.06	53.57	0.00	-12.80	0.00	0.00	0.00	0.00
16	<b>Net Profit / (Loss) after taxes, minority interest and shares of profit/(loss) of associates ((13 - 14 +15) ) *</b>								
		<b>324.10</b>	<b>408.91</b>	<b>80.74</b>	<b>966.23</b>	<b>350.04</b>	<b>317.58</b>	<b>112.28</b>	<b>981.27</b>
17	Paid-up equity share capital of face value Rs.10/- each								
		1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08
18	Reserve excluding Revaluation Reserves as per balance sheet of previous a/c. year								
		-----	-----	-----	7299.23	-----	-----	-----	7253.40
19.i	a) Basic and diluted EPS before Extraordinary items(f.v.10/- each) and Prior period Adjustment.(Not Annualised)								
		1.99	2.51	0.50	5.92	2.15	1.95	0.69	6.02
19.ii	b) Basic and diluted EPS after Extraordinary items (f.v.10/- each) and Prior period Adjustment.(Not Annualised)								
		1.99	2.51	0.50	5.92	2.15	1.95	0.69	6.02
PART - II									
A PARTICULARS OF SHAREHOLDING									
1	Public Shareholding:								
	-Number of shares	10972268	10974088	11589374	10974088	10972268	10974088	11589374	10974088
	-Percentage of Shareholding	67.27	67.28	71.05	67.28	67.27	67.28	71.05	67.28
2	Promoters and Promoter group Shareholding:								
	a) Pledged/Encumbered								
	-Number of shares	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	-Percentage of Shareholding (as a %of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	-Percentage of Shareholding (as a %of the total share capital of the Company)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-encumbered								
	-Number of shares	5338532	5336712	4721426	5336712	5338532	5336712	4721426	5336712
	-Percentage of Shareholding (as a %of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	-Percentage of Shareholding (as a %of the total share capital of the Company)	32.73	32.72	28.95	32.72	32.73	32.72	28.95	32.72
	Particulars	Quarter ended on 30.06.2013							
B INVESTOR COMPLAINTS									
	Pending at the beginning of the quarter	NIL							
	Received during the quarter	2							
	Disposed of during the quarter	2							
	Remaining unresolved at the end of the quarter	NIL							

**NOTES:-**

- The above results were reviewed by the audit committee and approved by by the Board of Directors at its meeting held on 13.08.2013.
- Previous year figures are regrouped/reclassified to confirm to the current year's presentation.
- Since the revenue from different segment is less than 10% of total revenue,segment wise results are not given.
- Statutory Auditors has carried out limited review for the quarterly result for quarter ended 30.06.2013.
- Consolidated results includes results of its two subsidiary Company.

Place : Ahmedabad.  
Date : 13.08.2013

for LINCOLN PHARMACEUTICALS LIMITED

sd/  
(Mahendra G. Patel)  
Managing Director